

ARVIND REMEDIES LIMITED
CORPORATE OFFICE: 38, 39 & 40, SIDCO INDUSTRIAL ESTATE, KAKKALUR - 602 003 TIRUVALLUR DIST, TN
AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2016
CIN: L24231TN1988PLC015882

PART-I

(Amount Rs. In Lakhs)

SI No	PARTICULARS	FOR THE QUARTER ENDED			FOR THE YEAR ENDED (9 MONTHS)
		30.06.2016 (Unaudited)	31.03.2016 (Audited)	30.06.2015 (Unaudited)	31.03.2016 (Audited)
1	Income from Operations				
	a) Net Sales (net of Excise Duty)	145.37	244.72	1,206.19	1,075.16
	b) Other Operating Income		1.21	8.08	4.52
	Total Income from Operations (net)	145.37	245.93	1,214.26	1,079.68
2	Expenses				
	a) Cost of Materials consumed	118.14	228.29	1,037.85	784.51
	b) Purchase of Stock in Trade			-	
	c) Change in Inventories of Finished goods, Work in Progress and Stock in Trade	(35.19)	18.43	(17.67)	23.08
	d) Employee Benefits Expenses	62.47	120.99	127.71	279.79
	e) Depreciation and Amortization Expenses	600.00	719.82	631.48	1,898.34
	f) Other Expenses	31.05	9425.94	234.31	9,476.83
	Total Expenses	776.47	10,513.47	2,013.67	12,462.55
3	Profit from Operations before other Income, Finance Costs and Exceptional Items (1-2)	(631.10)	(10,267.54)	(799.40)	(11,382.87)
4	Other Income	72.46	353.13	-	353.13
5	Profit from ordinary activities before Finance Costs and Exceptional Items (3+4)	(558.64)	(9,914.41)	(799.40)	(11,029.74)
6	Finance Costs	0.03	0.05	(377.44)	101.89
7	Profit from ordinary activities after Finance Costs but before Exceptional Items (5-6)	(558.67)	(9,914.46)	(421.95)	(11,131.63)
8	Exceptional Items (Provision for doubtful debts)	(2,045.25)	-	-	-
	Obsolete Items Written off				
9	Profit from ordinary activities before Tax (7-8)	(2,603.91)	(9,914.46)	(421.95)	(11,131.63)
10	Tax Expenses				
	Current Tax		-	-	-
	MAT Credit Entitlement			-	
	Deferred Tax Charge / (Credit)			-	
	Income Tax for earlier year			-	
			-	-	-
11	Net Profit from ordinary activities after Tax (9-10)	(2,603.91)	(9,914.46)	(421.95)	(11,131.63)
12	Extra Ordinary Items (Net of Tax Expenses)		-	-	-
13	Net Profit for the period (11-12)	(2,603.91)	(9,914.46)	(421.95)	(11,131.63)
14	Paid up Equity Share Capital (Face Value Rs.10/-)	6,812.60	6,812.60	6,812.60	6,812.60
15	Reserves (Excluding Revaluation Reserve) (as per Balance Sheet of previous accounting year)	(22,172.29)	(22,172.29)	(11,040.66)	(22,172.29)
16	Earning per Share (Before Extra Ordinary Items) (not annualised) (Rs)				
	a) Basic	(0.82)	(0.16)	(0.62)	(16.34)
	b) Diluted	(0.82)	(0.16)	(0.62)	(16.34)
16	Earning per Share (After Extra Ordinary Items) (not annualised) (Rs)				
	a) Basic	(3.82)	(0.16)	(0.62)	(16.34)
	b) Diluted	(3.82)	(0.16)	(0.62)	(16.34)



PART-II

Sl No	PARTICULARS	FOR THE QUARTER ENDED	FOR THE QUARTER ENDED	FOR THE 9 MONTHS ENDED
		30.06.2016	31.03.2016	31.03.2016
A	Particulars of Shareholding			
1	Public Shareholding			
	a) Number of Shares	6,56,90,444	6,56,90,444	6,56,90,444
	b) Percentage of Shareholding	96.42%	96.42%	96.42%
2	Promoters and Promoters group shareholding			
	a) Encumbered / Pledged			
	- Number of Shares	24,25,556	24,25,556	24,25,556
	- Percentage of Shares (as a % of total shareholding of promoter and promoters group)	99.59%	99.59%	99.59%
	- Percentage of Shares (as % of total Share capital of the company)	3.56%	3.56%	3.56%
	b) Non-Encumbered			
	- Number of Shares	10,000	10,000	10,000
	- Percentage of Shares (as a % of total shareholding of promoter and promoters group)	0.41%	0.41%	0.41%
	- Percentage of Shares (as % of total Share capital of the company)	0.01%	0.01%	0.01%

B	INVESTORS COMPLAINTS	For the quarter		
	Pending at the beginning of the quarter	0		
	Received during the Quarter	4		
	Disposed of during the quarter	4		
	Remaining Unresolved at the end of the quarter	0		

NOTES

1	The above unaudited financial results as reviewed by the Audit Committee were taken on record by the Board of Directors in its adjourned meeting held on 12th August 2016.
2	The Previous year's/Period's figures have been regrouped/rearranged wherever considered necessary.
3	The Company operates in one business segment only, i.e. Pharma formulation (Manufacturing and trading). As such, it does not have any reportable business segment.
4	The Trading of Company Shares was suspended from 27th November 2015 due to non-compliance clause 41 of listing agreement. Application will be submitted to the exchanges for revocation of suspension.
5	Since some the Debtors outstanding were for morethan one year it was decided to make provision for doubtful debts Rs. 2045.25 lakhs

Place: Chennai
Date : 12.08 2016

for Arvind Remedies Limited

Dr. B Arvind Shah

Managing Director

